You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder
SBC: Biomedical Development Corporation Topic: 103DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Real-Time Oxygen Monitoring for Tissue Health: Peripheral Artery Disease Application
SBC: PROFUSA, INC. Topic: NHLBIDESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Measuring Bladder Permeability with MRI using a Novel Contrast Agent Formulation
SBC: Lipella Pharmaceuticals Inc. Topic: 400DESCRIPTION provided by applicant This project entails the development of a novel dual component MRI contrast agent formulation for the detecting permeability in the luminal surface of the urinary bladder The purpose of having such a test is ultimately to allow clinicians in certain circumstances to differentially diagnose a chronic non infectious inflammation of the urinary bladder from a ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Optimizing HaploSeq for whole-genome phased haplotypes in biomedical applications
SBC: ARIMA GENOMICS, INC. Topic: 172DESCRIPTION provided by applicant Phenomenal advances in DNA sequencing technologies have enabled systematic identification of genetic variants in human individuals and the recent FDA marketing authorization of the first next generation genome sequencer signals the arrival of a new era of pharmacogenomics and personalized medicine Nevertheless DNA sequencing alone fails to provide complete i ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Rapid Diagnostics for Mucormycosis
SBC: VITALEX BIOSCIENCES LLC Topic: NIAIDDESCRIPTION provided by applicant Mucormycosis most commonly caused by Rhizopus oryzae is a life threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis DKA neutropenia corticosteroid use and or increased serum iron Because of the rising prevalence of these risk factors the incidence of mucormycosis has risen Despite disfiguring surgery and aggressive ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
A Low-Cost Portable Multiplex Serum Molecular Test for HBV and HCV Detection
SBC: LENIMA FIELD DIAGNOSTICS LLC Topic: RDESCRIPTION provided by applicant Hepatitis B HB and hepatitis C HC are two of the most widespread infections worldwide caused by the blood borne HB virus HBV and HC virus HCV respectively About million and million people suffer from chronic HB CHB and chronic HC CHC respectively while about and people die each year due to the consequence of HB and ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Protein Sequencing Tools for Biological Therapeutics
SBC: PROTEIN METRICS INC Topic: 400DESCRIPTION provided by applicant Mass spectrometry has become a method of choice for identifying and characterizing small quantities of proteins in complex mixtures However the ability to perform the identification in a high throughput fashion has depended on the availability of high quality protein sequence databases This means that proteins from organisms with unsequenced or poorly sequen ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
A Visual Assessment System for Retinal Function/Drug Discovery
SBC: AFASCI INC Topic: NDESCRIPTION provided by applicant Preclinical evaluation of treatment strategies for retinal neurodegenerative diseases is highly dependent on mouse models Classical methods to assess the visual function of animals such as electroretinogram ERG which measures electrical responses in the retina do not address connections between the eye and brain or visual perception by the visual system ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Antibodies for Biofilm Infections
SBC: TRELLIS BIOSCIENCE, INC. Topic: NIAIDDESCRIPTION provided by applicant About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs betwen the two states with ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Neurotrophic Agents for Treating Parkinson's Disaese
SBC: SENEB BIOSCIENCES INC Topic: 102DESCRIPTION provided by applicant Parkinsonandapos s disease PD is a neurodegenerative disorder characterized by motor function and eventually cognitive decline GM depletion is validated as a therapeutic target for Parkinsonandapos s disease PD in clinical studies in which GM replacement stabilized motor function loss and may be disease modifying However GM has poor pharmacologic prop ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health